跳至主要内容
临床试验/NCT00131118
NCT00131118已完成2 期

Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

Novartis Pharmaceuticals18 个研究点 分布在 1 个国家目标入组 127 人开始时间: 2004年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
127
试验地点
18
主要终点
Long-term safety of two different zoledronic acid doses over an additional 12 months in patients who have completed one year treatment in CZOL446H2202

研究概览

简要总结

This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Have completed the core CZOL446H2202 study
  • Males or females between 1-17 years of age

排除标准

  • Deformity or abnormality which would prevent spine bone density from being done
  • Any surgical bone-lengthening procedure
  • Any kidney diseases or abnormalities
  • Low calcium or vitamin D levels in the blood
  • Other protocol-defined inclusion/exclusion criteria may apply.

结局指标

主要结局

Long-term safety of two different zoledronic acid doses over an additional 12 months in patients who have completed one year treatment in CZOL446H2202

次要结局

  • Measure percentage change of lumbar spine bone mineral density at month 18 and 24 compared to baseline in the core study.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验